IL79289A - Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus - Google Patents

Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus

Info

Publication number
IL79289A
IL79289A IL79289A IL7928986A IL79289A IL 79289 A IL79289 A IL 79289A IL 79289 A IL79289 A IL 79289A IL 7928986 A IL7928986 A IL 7928986A IL 79289 A IL79289 A IL 79289A
Authority
IL
Israel
Prior art keywords
genetic material
foreign genetic
epithelial cells
keratinocytes
introduction
Prior art date
Application number
IL79289A
Other languages
English (en)
Other versions
IL79289A0 (en
Original Assignee
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25026444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL79289(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Whitehead Biomedical Inst filed Critical Whitehead Biomedical Inst
Publication of IL79289A0 publication Critical patent/IL79289A0/xx
Publication of IL79289A publication Critical patent/IL79289A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/43—Hormones, e.g. dexamethasone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL79289A 1985-07-05 1986-06-30 Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus IL79289A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75246685A 1985-07-05 1985-07-05

Publications (2)

Publication Number Publication Date
IL79289A0 IL79289A0 (en) 1986-09-30
IL79289A true IL79289A (en) 1992-01-15

Family

ID=25026444

Family Applications (1)

Application Number Title Priority Date Filing Date
IL79289A IL79289A (en) 1985-07-05 1986-06-30 Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus

Country Status (9)

Country Link
US (2) US4868116A (de)
EP (1) EP0228458B2 (de)
JP (1) JP2703893B2 (de)
AT (1) ATE68013T1 (de)
AU (1) AU6131086A (de)
CA (1) CA1339962C (de)
DE (1) DE3681787D1 (de)
IL (1) IL79289A (de)
WO (1) WO1987000201A1 (de)

Families Citing this family (356)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266480A (en) * 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE3855681T2 (de) * 1987-05-01 1997-05-28 The General Hospital Corp., Boston, Mass. Transkaryotische Einpflanzung
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
DE3852823T2 (de) * 1987-09-11 1995-05-24 Hughes Howard Med Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US6544771B1 (en) 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
JP2914692B2 (ja) * 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
EP0400047B1 (de) 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modifizierte hepatozyten und deren anwendung
US5580776A (en) * 1988-02-05 1996-12-03 Howard Hughes Medical Institute Modified hepatocytes and uses therefor
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
ZA892518B (en) * 1988-04-08 1989-12-27 Intracel Corp Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells
US6645942B1 (en) 1988-04-28 2003-11-11 The Salk Institute For Biological Studies Somatic cell gene therapy
WO1990001266A1 (en) * 1988-08-04 1990-02-22 President And Fellows Of Harvard College Transplantig cultured epithelial cells with a desired phenotypic trait
DE69033975T2 (de) * 1989-01-23 2002-10-02 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanttherapien für Infektionen und hyperproliferative Störungen
US5605821A (en) * 1989-03-08 1997-02-25 Board Of Regents Of The University Of Oklahoma Expression control sequences of the P-selectin gene
US5624824A (en) * 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5091173A (en) * 1989-06-29 1992-02-25 The University Of Dundee Hair growth composition
US5817075A (en) * 1989-08-14 1998-10-06 Photogenesis, Inc. Method for preparation and transplantation of planar implants and surgical instrument therefor
SG49267A1 (en) 1989-08-14 1998-05-18 Photogenesis Inc Surgical instrument and cell isolation and transplantation
US6514238B1 (en) * 1989-08-14 2003-02-04 Photogenesis, Inc. Method for preparation and transplantation of volute grafts and surgical instrument therefor
DE69032100T2 (de) * 1989-08-14 1998-10-29 Photogenesis Inc., Los Angeles, Calif. Chirurgisches instrument und zellisolierung
US6984487B1 (en) 1989-08-22 2006-01-10 Hsc Research Development Corporation Cystic fibrosis gene
US5543399A (en) * 1989-08-22 1996-08-06 Hsc Research & Development Limited Partnership Cystic fibrosis transmembrane conductance regulator (CFTR) protein
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5863770A (en) * 1989-08-22 1999-01-26 Hsc Research And Development Limited Partnership Stable meterologous propagation of CFTR protein variant cDNA
US6063913A (en) * 1989-08-22 2000-05-16 Hsc Research And Development Limited Partnership Stable heterologous propagation CFTR protein variant cDNA
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
EP0897987B1 (de) * 1989-10-24 2001-02-28 Chiron Corporation Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5423778A (en) * 1989-12-14 1995-06-13 Elof Eriksson System and method for transplantation of cells
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
US6090790A (en) 1989-12-14 2000-07-18 Eriksson; Elof Gene delivery by microneedle injection
DE69132616T2 (de) * 1990-01-12 2002-02-21 Hsc Research Development Corp., Toronto Introns und exons des gens für cystische fibrose sowie mutationen an mehreren stellen des gens
US5068315A (en) * 1990-04-12 1991-11-26 University Of Dundee Composition for the regulation of hair growth
EP0528842A4 (en) * 1990-04-17 1993-06-30 Pherin Corporation Methods of tissue implantation
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US6027722A (en) * 1990-10-25 2000-02-22 Nature Technology Corporation Vectors for gene transfer
ATE169061T1 (de) * 1990-10-25 1998-08-15 Clague Pitman Hodgson Methode des gentransfers mittels retrotransposons
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US6045791A (en) * 1992-03-06 2000-04-04 Photogenesis, Inc. Retinal pigment epithelium transplantation
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
EP0661987B1 (de) 1992-09-16 1998-01-14 Creative Biomolecules, Inc. Morphogeninduzierte regenerierung der leber
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
WO1994020608A1 (en) 1993-03-12 1994-09-15 Creighton University Improved vectors for gene therapy
AU6829994A (en) * 1993-05-10 1994-12-12 Regents Of The University Of Michigan, The Gene transfer into pancreatic and biliary epithelial cells
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
IL113052A0 (en) 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
US5850002A (en) * 1994-04-20 1998-12-15 Washington University Animal models for loss and gain of Hox11 function
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US7078511B1 (en) 1994-06-23 2006-07-18 Massachusette Institute Of Technology Class BI and CI scavenger receptors
US5962322A (en) * 1996-11-15 1999-10-05 Massachusetts Institute Of Technology Methods for modulation of cholesterol transport
US5695993A (en) * 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US5898066A (en) * 1994-08-26 1999-04-27 Children's Medical Center Corporation Trophic factors for central nervous system regeneration
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5868728A (en) * 1995-02-28 1999-02-09 Photogenesis, Inc. Medical linear actuator for surgical delivery, manipulation, and extraction
US7422574B2 (en) 1995-05-19 2008-09-09 Applied Tissue Technologies, Llc Microseeding device for gene delivery by microneedle injection
US20030190753A1 (en) * 1995-11-09 2003-10-09 Nature Technology Corporation Vectors for gene transfer
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US5945100A (en) * 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5948681A (en) * 1996-08-14 1999-09-07 Children's Hospital Of Philadelphia Non-viral vehicles for use in gene transfer
US6108637A (en) 1996-09-03 2000-08-22 Nielsen Media Research, Inc. Content display monitor
WO1998020041A1 (en) 1996-11-08 1998-05-14 Oklahoma Medical Research Foundation Endothelium specific expression regulated by epcr control elements
US6643696B2 (en) 1997-03-21 2003-11-04 Owen Davis Method and apparatus for tracking client interaction with a network resource and creating client profiles and resource database
CA2205076A1 (en) 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
US20050096288A1 (en) * 1997-06-13 2005-05-05 Aragene, Inc. Lipoproteins as nucleic acid vectors
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6096303A (en) * 1997-07-31 2000-08-01 Medical College Of Georgia Research Institute, Inc. Method to enhance treatment of cystic tumors
US20020099040A1 (en) * 1997-09-05 2002-07-25 Monty Krieger Sr-bi antagonists and use thereof as contraceptives and in the treatment of steroidal overproduction
US6395876B1 (en) 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
AU2018999A (en) 1997-12-31 1999-07-19 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
US6946445B1 (en) * 1998-03-13 2005-09-20 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2344653A1 (en) 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
IL139321A0 (en) * 1999-03-03 2001-11-25 Biogen Inc Methods and compositions for modulating lipid metabolism
US6342356B1 (en) 1999-03-12 2002-01-29 Gpc Biotech, Inc. Methods and regents for identifying synthetic genetic elements
US6328762B1 (en) * 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
AUPQ206399A0 (en) 1999-08-06 1999-08-26 Imr Worldwide Pty Ltd. Network user measurement system and method
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US8168178B2 (en) * 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6632608B2 (en) 1999-12-30 2003-10-14 President And Fellows Of Harvard College Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
WO2001071018A2 (en) * 2000-03-22 2001-09-27 Board Of Trustees Of The University Of Arkansas Secreting products from skin by adeno-associated virus (aav) gene transfer
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
EP1702983A3 (de) 2000-04-13 2007-01-10 Medical University of South Carolina Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisenseolinukleotide sowie Anwendungen dafür
EP1287125B1 (de) 2000-04-28 2009-07-29 Asklepios Biopharmaceutical, Inc. Für das dystrophin-minigen kodierende dna-sequenzen und verfahren zu deren verwendung
WO2002014867A2 (en) * 2000-08-11 2002-02-21 Agilix Corporation Ultra-sensitive detection systems
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
AU9684601A (en) 2000-10-12 2002-04-22 Univ Rochester Compositions that inhibit proliferation of cancer cells
US7423142B2 (en) * 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2002072790A2 (en) 2001-03-14 2002-09-19 Myriad Genetics, Inc Tsg101-gag interaction and use thereof
AU2002303277A1 (en) * 2001-04-06 2002-10-21 Vladimir Larionov Artificial chromosomes that can shuttle between bacteria, yeast, and mammalian cells
US7262174B2 (en) * 2001-05-09 2007-08-28 Geron Corporation Treatment for wounds
EP1404713A4 (de) 2001-05-24 2004-09-22 Human Dna Technology Inc Neues keratinocyte growth factor 2 analogon in haarfollikeln
AU2001286171B2 (en) * 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
US20070015144A9 (en) * 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
US20030095952A1 (en) * 2001-06-13 2003-05-22 Krause Diane S. Multi-organ engraftment with a single bone marrow-derived stem cell
ES2184623B1 (es) * 2001-06-29 2004-09-16 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (C.I.E.M.A.T.) Piel artificial autologa secretora de leptina y metodo de obtencion.
EP1900815B1 (de) 2001-07-12 2016-09-07 University of Massachusetts In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
ES2609014T3 (es) 2001-07-12 2017-04-18 University Of Massachusetts Producción in vivo de ARN de interferencia pequeños que median el silenciamiento génico
US8257737B2 (en) * 2001-08-09 2012-09-04 Giuseppe Intini Tissue implants and methods for making and using same
US7045350B2 (en) * 2001-08-30 2006-05-16 Mount Sinai School Of Medicine Of New York University Alternatively spliced circulating tissue factor
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
MXPA04002848A (es) * 2001-09-28 2005-06-06 Esperion Therapeutics Inc Prevencion y tratamiento de restenosis por administracion local de medicamento.
WO2003029429A2 (en) * 2001-10-03 2003-04-10 Selective Genetics, Inc. Traversal of nucleic acid molecules through a fluid space and expression in repair cells
AU2002332027A1 (en) * 2001-10-04 2003-04-14 The Government Of The United States Of America, As Tandem repeat markers
US7745418B2 (en) * 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
AU2002365271B2 (en) * 2001-11-06 2008-12-11 Agilix Corporation Sensitive coded detection systems
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US6939554B2 (en) * 2002-02-05 2005-09-06 Michigan Biotechnology Institute Antimicrobial polymer
JP2005517468A (ja) * 2002-02-14 2005-06-16 フォトジェネシス インコーポレイテッド 網膜下移植装置および同装置と共に使用されるカニューレ
US20060035810A1 (en) * 2002-03-18 2006-02-16 Shears Stephen B Regulation of ins(3456)p4 signalling by a reversible kinase phosphatase and methods and compositions related thereto
WO2003089624A2 (en) * 2002-03-25 2003-10-30 Uab Research Foundation Fc receptor homolog, reagents, and uses thereof
NZ537006A (en) * 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
US7208467B2 (en) 2002-06-07 2007-04-24 Monty Krieger Lipid-altering compositions for the treatment of infertility
US6943021B2 (en) * 2002-06-07 2005-09-13 Mattek Corporation Three dimensional vaginal tissue model containing immune cells
US8271778B1 (en) 2002-07-24 2012-09-18 The Nielsen Company (Us), Llc System and method for monitoring secure data on a network
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
JP2006500030A (ja) 2002-09-20 2006-01-05 イェール ユニバーシティ リボスイッチ、その使用方法、ならびにリボスイッチとともに用いるための組成物
AU2003282550C1 (en) * 2002-10-09 2008-09-25 Tolerx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
EP2258724A1 (de) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulierung von Immunantworten mittels multimeriserter Anti-CD83 Antikörper
US7803365B2 (en) * 2002-12-02 2010-09-28 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US9388427B2 (en) * 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
WO2004064785A2 (en) 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
DE10302421A1 (de) * 2003-01-21 2004-07-29 Ribopharma Ag Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
US20050106124A1 (en) * 2003-02-25 2005-05-19 Sehgal Lakshman R. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US20050186289A1 (en) * 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
CA2524883C (en) 2003-05-16 2014-07-22 Universite Laval Potassium-chloride cotransporter kcc2 modulation for treatment of pain
AU2004252442B2 (en) 2003-06-02 2010-04-08 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of FNAi
ES2712695T3 (es) 2003-06-02 2019-05-14 Univ Massachusetts Métodos y composiciones para controlar la eficacia de la silenciación del ARN
ATE423134T1 (de) 2003-06-10 2009-03-15 Nsgene As Verbesserte sezernierung von neublastin
EP2441474B1 (de) 2003-10-17 2015-08-05 Joslin Diabetes Center, Inc. Verfahren und Zusammensetzungen zur Modulation der Adipozytfunktion
ES2342397T3 (es) 2003-10-20 2010-07-06 Nsgene A/S Vector virico para su uso en terapia genica in vivo de la enfermedad de parkinson.
EP1918000A2 (de) 2003-11-05 2008-05-07 Schering Corporation Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände
EP1711517A4 (de) 2004-01-21 2008-02-13 Univ Utah Res Found MUTANTER NATRIUMKANAL NAv1.7 UND DAMIT VERBUNDENE VERFAHREN
US20050272678A1 (en) * 2004-02-11 2005-12-08 Bodine Peter Van N BMP-6 estrogen responsive element and methods of use thereof
WO2005086934A2 (en) * 2004-03-10 2005-09-22 Board Of Regents, The University Of Texas System Enriched cdna expression libraries and methods of making and using same
ES2423060T3 (es) 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
CN1950397B (zh) 2004-03-30 2012-05-16 Ns基因公司 生长因子NsG33的治疗用途
JP2007531537A (ja) * 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
DK1773872T3 (en) 2004-05-21 2017-05-08 Uab Res Found VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
US20060021075A1 (en) * 2004-07-15 2006-01-26 Chyung-Ru Wang Group 1 CD1 transgenic mice and their uses
US20090136552A1 (en) * 2004-07-30 2009-05-28 Mette Gronborg Growth factors nsg28, nsg30, and nsg32
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
US20060063187A1 (en) * 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders
EP1799812A4 (de) 2004-09-16 2009-09-09 Gamida Cell Ltd Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen
US20080131433A1 (en) * 2004-09-27 2008-06-05 The Uab Research Foundation Fc Receptor Homolog Antibodies And Uses Thereof
HUE038099T2 (hu) 2004-12-21 2018-09-28 Musc Found For Res Dev Kompozíciók és módszerek sebgyógyulás és szöveti regeneráció elõsegítésére
EP1851551A2 (de) * 2005-02-03 2007-11-07 Perkinelmer Las, Inc. Ultrasensitive detektionssysteme mit mehrdimensionalen signalen
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
EP1934244A2 (de) * 2005-10-06 2008-06-25 Emthrax LLC Verfahren und zusammensetzungen in verbindung mit milzbrandsporen-glycoproteinen als impfstoffe
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2395076A1 (de) 2005-10-14 2011-12-14 MUSC Foundation For Research Development Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
WO2007056326A2 (en) * 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
WO2007056331A2 (en) 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
EP3023497A1 (de) 2005-11-18 2016-05-25 Glenmark Pharmaceuticals S.A. Anti-alpha2-integrin-antikörper und deren verwendungen
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP1974052A2 (de) * 2005-12-21 2008-10-01 Yale University Verfahren und zusammensetzungen in verbindung mit der modulation von riboschaltern
EP2913056A1 (de) * 2006-01-05 2015-09-02 The University of Utah Research Foundation Verfahren und Zusammensetzungen in Zusammenhang mit der Verbesserung von Eigenschaften pharmakologischer Wirkstoffe für das Nervensystem
AU2007223427A1 (en) * 2006-03-01 2007-09-13 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
CA2647728C (en) 2006-03-31 2014-12-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 gene
WO2007127919A2 (en) * 2006-04-28 2007-11-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the jc virus
CN101484588B (zh) 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
CA2652770A1 (en) 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
CA2653451C (en) 2006-05-22 2015-12-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
BRPI0712607A8 (pt) 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
WO2007150069A2 (en) 2006-06-23 2007-12-27 Myriad Genetics, Inc. Dpyd gene variants and use thereof
WO2008033866A2 (en) * 2006-09-11 2008-03-20 Yale University Methods and compositions for the use of lysine riboswitches
EP3034083B1 (de) 2006-09-21 2020-12-09 University of Rochester Antisense-oligonukleotide zur behandlung von myotoner dystrophie
CN101600451A (zh) 2006-12-11 2009-12-09 犹他大学研究基金会 用于治疗病理性血管生成和血管通透性的组合物和方法
WO2008089440A2 (en) 2007-01-18 2008-07-24 University Of Utah Research Foundation Compositions and methods for detecting, treating, or preventing reductive stress
EP2629094A1 (de) 2007-01-24 2013-08-21 Carnegie Mellon University Optische Biosensoren
US8097588B2 (en) * 2007-02-08 2012-01-17 Sanford-Burnham Medical Research Institute Trophinin-binding peptides and uses thereof
JP2010521977A (ja) 2007-03-22 2010-07-01 イェール ユニバーシティー オルタナティブスプライシングを調節するリボスイッチに関する方法および組成物
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
CA2687024A1 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
WO2008150884A1 (en) * 2007-05-29 2008-12-11 Yale University Methods and compositions related to riboswitches that control alternative splicing and rna processing
WO2008156987A2 (en) 2007-05-29 2008-12-24 Yale University Riboswitches and methods and compositions for use of and with riboswitches
CN103215269B (zh) 2007-07-05 2015-01-21 诺瓦提斯公司 用于治疗病毒感染的dsRNA
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2195331B1 (de) 2007-08-28 2013-11-20 Uab Research Foundation Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren
US7951785B2 (en) 2007-09-21 2011-05-31 California Institute Of Technology NFIA in glial fate determination, glioma therapy and astrocytoma treatment
PT2222697E (pt) 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
CA2706317C (en) * 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Doc1 compositions and methods for treating cancer
EP2848688A1 (de) 2007-12-10 2015-03-18 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
AU2009221775B2 (en) 2008-03-05 2015-05-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 and VEGF genes
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
AU2009244308A1 (en) 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
AU2008360658B2 (en) 2008-08-15 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S0X9, prostaglandin D2 and retinoic acid for treating pigmentary conditions and melanoma
EP3208337A1 (de) 2008-09-02 2017-08-23 Alnylam Pharmaceuticals, Inc. Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
WO2010036962A1 (en) 2008-09-25 2010-04-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
AU2009307677C1 (en) 2008-10-20 2022-09-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
US9447176B2 (en) 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
CA2746514C (en) 2008-12-10 2018-11-27 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
EP2389191A2 (de) 2009-01-23 2011-11-30 NsGene A/S Expression von neuropeptiden in säugetierzellen
EP2401302A4 (de) 2009-02-24 2013-10-09 Alexion Pharma Inc Antikörper mit therapeutischen mimetischen tpo-/epo-peptiden
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
ES2900277T3 (es) 2009-03-20 2022-03-16 Mesoblast Inc Producción de células pluripotentes reprogramadas
US20120107331A1 (en) 2009-05-15 2012-05-03 Yale University Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
US9149024B2 (en) 2009-06-22 2015-10-06 Massachusetts Eye & Ear Infirmary Islet1 (Isl1) and hearing loss
EP3064595B1 (de) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Verfahren für zellproliferationsbedingte erkrankungen
EP2498825B1 (de) 2009-11-09 2017-03-29 Genepod Therapeutics Ab Neues virales vektorkonstrukt zur neuronenspezifischen kontinuierlichen dopa-synthese in vivo
EP2524042A2 (de) 2010-01-12 2012-11-21 Yale University Strukturierte rna-motive sowie verbindungen und verfahren zu ihrer verwendung
BR112012017483A2 (pt) 2010-01-14 2019-09-24 Haplomics Inc previsão e redução de aloimunogenicidade de terapêuticos de proteína
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
CA2792291A1 (en) 2010-03-29 2011-10-06 Kumamoto University Sirna therapy for transthyretin (ttr) related ocular amyloidosis
JP6022441B2 (ja) 2010-04-30 2016-11-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗Ｃ５ａ抗体およびその抗体の使用のための方法
KR101886029B1 (ko) 2010-10-01 2018-08-07 호바 세라퓨틱스 에이피에스 무해자극통증, 통각과민증, 자발통증 및 헛통증의 치료를 위한 메테오린의 용도
WO2012051301A1 (en) 2010-10-12 2012-04-19 President And Fellows Of Harvard College Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
US8815942B2 (en) 2010-10-20 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
CN103608680A (zh) 2010-12-14 2014-02-26 詹姆士·W·里拉尔德 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
CN103517712A (zh) 2010-12-15 2014-01-15 神经佐剂股份有限公司 神经肽类似物、组合物和治疗疼痛的方法
WO2012092299A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
US10130687B2 (en) 2011-01-05 2018-11-20 Rhode Island Hospital Compositions and methods for the treatment of orthopedic disease or injury
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
US20130156803A1 (en) 2011-06-04 2013-06-20 Rochester General Hospital Research Institute Compositions and methods related to p6
EP3388068A1 (de) 2011-06-21 2018-10-17 Alnylam Pharmaceuticals, Inc. Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
KR20230084331A (ko) 2011-06-21 2023-06-12 알닐람 파마슈티칼스 인코포레이티드 아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
EP2753347B1 (de) 2011-09-05 2016-08-03 NsGene A/S Behandlung von allodynie, hyperalgesie, spontanen schmerzen und phantomschmerzen
CN104204192A (zh) 2012-02-13 2014-12-10 加米达细胞有限公司 间充质干细胞调理的基质及其产生和使用方法
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
WO2014018851A1 (en) 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
WO2014113540A1 (en) 2013-01-16 2014-07-24 Iowa State University Research Foundation, Inc. A deep intronic target for splicing correction on spinal muscular atrophy gene
EP2769732A1 (de) 2013-02-22 2014-08-27 Sanofi Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
US20160002316A1 (en) 2013-02-22 2016-01-07 Joslin Diabetes Center Serpins: methods of therapeutic beta-cell regeneration and function
EP2851086A1 (de) 2013-09-20 2015-03-25 Sanofi Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
KR102127358B1 (ko) 2013-03-13 2020-06-29 지니위브 바이오사이언시스, 인코포레이티드 비-복제 형질도입 입자 및 형질도입 입자-기반 리포터 시스템
US20140379421A1 (en) 2013-06-25 2014-12-25 The Nielsen Company (Us), Llc Methods and apparatus to characterize households with media meter data
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
US9277265B2 (en) 2014-02-11 2016-03-01 The Nielsen Company (Us), Llc Methods and apparatus to calculate video-on-demand and dynamically inserted advertisement viewing probability
US10214741B2 (en) 2014-02-14 2019-02-26 University Of Utah Research Foundation Methods and compositions for inhibiting retinopathy of prematurity
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EP3142679A4 (de) 2014-03-25 2017-10-11 University of Utah Research Foundation Peptidinhibitoren der bcr-abl-oligomerisierung
WO2016014353A1 (en) 2014-07-24 2016-01-28 Massachusetts Eye & Ear Infirmary Rpgr gene therapy for retinitis pigmentosa
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
US10632151B2 (en) 2015-01-22 2020-04-28 University Of Massachusetts Cancer immunotherapy
US20180215801A1 (en) 2015-01-29 2018-08-02 Board Of Trustees Of Michigan State University Cryptic polypeptides and uses thereof
PT3265568T (pt) 2015-03-06 2020-08-20 Massachusetts Eye & Ear Infirmary Terapias de aumento de genes para a degeneração hereditária da retina causada por mutações no gene prpf31
US10219039B2 (en) 2015-03-09 2019-02-26 The Nielsen Company (Us), Llc Methods and apparatus to assign viewers to media meter data
US20180042998A1 (en) 2015-03-10 2018-02-15 University Of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
EP3294334B1 (de) 2015-05-11 2020-07-08 The Johns Hopkins University Autoimmunantikörper zur verwendung bei der hemmung des wachstums von krebszellen
WO2016183585A1 (en) 2015-05-14 2016-11-17 Joslin Diabetes Center, Inc. Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
CN108136048A (zh) 2015-08-03 2018-06-08 米奥多巴有限公司 左旋多巴的系统合成和调节
US9848224B2 (en) 2015-08-27 2017-12-19 The Nielsen Company(Us), Llc Methods and apparatus to estimate demographics of a household
WO2017066796A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
EP4310503A3 (de) 2015-12-30 2024-03-20 Momenta Pharmaceuticals, Inc. Verfahren im zusammenhang mit biologika
US20190300864A1 (en) 2016-05-20 2019-10-03 Braingene Ab Destabilising domains for conditionally stabilising a protein
AU2017269839A1 (en) 2016-05-27 2018-11-22 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
WO2018001858A1 (en) 2016-06-27 2018-01-04 University Of Copenhagen Tailored assembly of a modular bud polypeptide
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
WO2018085444A1 (en) 2016-11-01 2018-05-11 Washington University COMPOSITIONS COMPRISING CelTOS IMMUNOGENS AND ANTIBODIES AND METHOD OF USE THEREOF
US12544441B2 (en) 2016-11-01 2026-02-10 Washington University Compositions comprising CelTOS immunogens and antibodies and method of use thereof
US10791355B2 (en) 2016-12-20 2020-09-29 The Nielsen Company (Us), Llc Methods and apparatus to determine probabilistic media viewing metrics
WO2018191599A1 (en) 2017-04-14 2018-10-18 University Of Massachusetts Brown fat-selective adipokines
CN110914295B (zh) 2017-06-28 2024-08-09 里珍纳龙药品有限公司 抗人乳头瘤病毒(hpv)抗原结合蛋白及其使用方法
BR112020001703B1 (pt) 2017-07-27 2024-01-02 Alexion Pharmaceuticals, Inc Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
CN111670033A (zh) 2017-10-18 2020-09-15 华盛顿大学 作为神经变性疾病或病症的治疗策略的显性阴性sarm1分子
EP3700928A1 (de) 2017-10-26 2020-09-02 Alexion Pharmaceuticals, Inc. Dosierung und verabreichung von anti-c5-antikörpern zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh) und atypischem hämolytisch-urämischem syndrom (ahus)
US11008602B2 (en) 2017-12-20 2021-05-18 Roche Molecular Systems, Inc. Non-replicative transduction particles and transduction particle-based reporter systems
US12508306B2 (en) 2018-04-25 2025-12-30 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
CA3099963A1 (en) 2018-05-11 2019-11-14 University Of Massachusetts Methods for improving leptin sensitivity for the treatment of obesity and diabetes
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
SG11202011815SA (en) 2018-06-01 2020-12-30 Sanofi Sa Combination therapy for treating hepatitis b virus infection
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
EP3814373A1 (de) 2018-06-28 2021-05-05 Alexion Pharmaceuticals, Inc. Verfahren zur herstellung von anti-c5 -antikörpern
MX2021000532A (es) 2018-07-19 2021-04-12 Regeneron Pharma Receptores antigénicos quiméricos con especificidad para bcma y usos de estos.
JP7571010B2 (ja) 2018-09-06 2024-10-22 モメンタ ファーマシューティカルズ インコーポレイテッド 連続細胞培養の方法
EA202191107A1 (ru) 2018-10-23 2021-09-17 Ридженерон Фармасьютикалз, Инк. T-клеточные рецепторы ny-eso-1 и способы их применения
MX2021004994A (es) 2018-10-30 2021-06-15 Alexion Pharma Inc Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
WO2020120649A1 (en) 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
WO2020136154A1 (en) 2018-12-27 2020-07-02 F. Hoffmann-La Roche Ag Non-replicative transduction particles and transduction particle-based reporter systems for detection of acinetobacter baumannii
AU2019419372B2 (en) 2018-12-31 2026-03-26 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
US11572595B2 (en) 2018-12-31 2023-02-07 Roche Molecular Systems, Inc. Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
US12600793B2 (en) 2019-07-24 2026-04-14 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with MAGE-A4 specificity and uses thereof
US20220356234A1 (en) 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
EP4038222A4 (de) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Verfahren und zusammensetzungen zur identifizierung von neoantigenen zur verwendung bei der behandlung und vorbeugung von krebs
CN114867493B (zh) 2019-10-04 2026-04-10 阿尔伯特爱因斯坦医学院 Kir3dl3是免疫系统的抑制性受体及其用途
JP2023505169A (ja) 2019-12-03 2023-02-08 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｂ型肝炎感染の治療における使用のためのインターフェロン会合抗原結合タンパク質
EP4069291A1 (de) 2019-12-03 2022-10-12 Evotec International GmbH Interferon-assoziierte antigenbindende proteine und verwendungen davon
AU2020407124A1 (en) 2019-12-20 2022-07-21 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1
EP4085156B1 (de) 2019-12-31 2023-10-25 F. Hoffmann-La Roche AG Quantitatives pcr-screening von induzierbaren prophagen aus bakterienisolaten
IL294988A (en) 2020-01-24 2022-09-01 Regeneron Pharma Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them
US12129496B2 (en) 2020-02-12 2024-10-29 Massachusetts Eye And Ear Infirmary Haplotype-based treatment of RP1 associated retinal degenerations
BR112022021450A2 (pt) 2020-04-24 2022-12-27 Millennium Pharm Inc O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
JP7648654B2 (ja) 2020-05-05 2025-03-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ２８ゼータ及びｃｄ３ゼータを含むｃａｒ
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
WO2022056497A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Single domain antibodies against cd33
CA3205574A1 (en) 2020-12-18 2022-06-23 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1
CN116615268A (zh) 2020-12-24 2023-08-18 诺沃库勒有限责任公司 在基因疗法中用于使用交变电场的方法和组合物
EP4320149A1 (de) 2021-04-09 2024-02-14 Takeda Pharmaceutical Company Limited Gegen komplementfaktor d gerichtete antikörper und verwendungen davon
PE20242205A1 (es) 2021-04-26 2024-11-19 Millennium Pharm Inc Anticuerpos anti-adgre2 y usos de los mismos
IL307939A (en) 2021-04-26 2023-12-01 Millennium Pharm Inc Anti-CLEC12A antibodies and uses thereof
JP2024516308A (ja) 2021-05-04 2024-04-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｍａｇｅ－ａ４特異性を有するキメラ抗原受容体及びその使用
CA3217602A1 (en) 2021-05-06 2022-11-10 Kenneth Petersen Prevention and treatment of chemotherapy-induced neuropathic pain
EP4351732A1 (de) 2021-06-09 2024-04-17 Evotec International GmbH Interferon-assoziierte antigenbindende proteine zur verwendung zur behandlung oder prävention von coronavirus-infektionen
US12492245B2 (en) 2021-09-21 2025-12-09 University Of South Carolina Anti-CCL8 antibodies and treatment of lung injury by CCL8 inhibition
PE20242001A1 (es) 2021-10-20 2024-09-27 Takeda Pharmaceuticals Co Composiciones que actuan sobre bcma y metodos de uso de estas
CN118488846A (zh) 2021-12-10 2024-08-13 霍巴治疗公司 伤害性疼痛的治疗
EP4507794A1 (de) 2022-04-11 2025-02-19 Vor Biopharma Inc. Bindemittel und verfahren zur verwendung davon
AU2023285085A1 (en) 2022-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024091669A1 (en) 2022-10-28 2024-05-02 Ginkgo Bioworks, Inc. Chimeric antigen receptors comprising an intracellular domain pair
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
JP2026506095A (ja) 2023-02-17 2026-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞
EP4687959A1 (de) 2023-03-24 2026-02-11 Cornell University Verwendung von t-zellen aus tumordränierenden lymphknoten zur chimären antigenrezeptor(car)-t-zelltherapie zur behandlung von krebs
WO2024213635A1 (en) 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
EP4698219A2 (de) 2023-04-17 2026-02-25 Washington University Alpha-hämolysin-zusammensetzungen und verfahren zur immunisierung gegen staphylococcus aureus
WO2024238565A1 (en) 2023-05-15 2024-11-21 Vor Biopharma Inc. Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
WO2024243511A1 (en) 2023-05-25 2024-11-28 Regeneron Pharmaceuticals, Inc. T cell receptors that bind presented hpv16-, mart1-, cmv-, ebv-, or influenza- peptides
WO2025255030A1 (en) 2024-06-03 2025-12-11 Cornell University Interferon gamma responsive chimeric t cell costimulatory receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016036A (en) * 1975-11-14 1977-04-05 Massachusetts Institute Of Technology Process for serially culturing keratinocytes
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4304866A (en) * 1979-11-14 1981-12-08 Massachusetts Institute Of Technology Transplantable sheets of living keratinous tissue
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4769317A (en) * 1983-06-14 1988-09-06 Hefton John M Process for growing human epidermis, product thereof
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3855681T2 (de) * 1987-05-01 1997-05-28 The General Hospital Corp., Boston, Mass. Transkaryotische Einpflanzung
EP0400047B1 (de) * 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modifizierte hepatozyten und deren anwendung
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy

Also Published As

Publication number Publication date
JPS63500492A (ja) 1988-02-25
US5698436A (en) 1997-12-16
EP0228458B2 (de) 1997-10-22
JP2703893B2 (ja) 1998-01-26
EP0228458A1 (de) 1987-07-15
US4868116A (en) 1989-09-19
CA1339962C (en) 1998-07-21
EP0228458B1 (de) 1991-10-02
WO1987000201A1 (en) 1987-01-15
DE3681787D1 (de) 1991-11-07
AU6131086A (en) 1987-01-30
ATE68013T1 (de) 1991-10-15
IL79289A0 (en) 1986-09-30

Similar Documents

Publication Publication Date Title
IL79289A0 (en) Introduction and expression of foreign genetic material in epithelial cells
UA27706C2 (uk) Спосіб одержання гетерологічного поліпептиду
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
MY102029A (en) Human factor viii, compositions containing it, methods and materials for use in its production
MD430C2 (ro) Procedeu de obţinere a interferonelor leucocitare umane
MX428A (es) Region regulatoria para expresion de gen heterologa en levadura.
ATE117375T1 (de) Transduktionsveränderte fibroblasten und ihre anwendung.
ES8704976A1 (es) Metodo pra la fabricacion de un polipeptido firiologicamente activo en el hombre.
EP0063953A3 (de) Bacillus-Klonierungsvektoren, rekombinante DNA-Moleküle, damit transformierte Bacilluswirte und Verfahren zur Expression fremder DNA-Sequenzen und zur Herstellung von dadurch kodierten Polypeptiden
ATE27000T1 (de) Expression von polypeptiden in hefen.
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
ES8303530A1 (es) Un procedimiento para la preparacion de un microorganismo que contiene un plasmido recombinante de un adn
ZA957846B (en) Overexpression of mammalian and viral proteins
DE3880468D1 (de) Rekombinante dns-expressionsvektoren.
DE69738586D1 (de) Hohe expressionsrate von proteinen
UA40625C2 (uk) Конструкція днк, рекомбінантний експресуючий вектор, спосіб одержання гетерологічного поліпептиду
ES8700868A1 (es) Metodo de aislamiento de un fragmento de gen que codifica por lo menos una porcion de una proteina.
DE69828193D1 (de) Hyaluronan synthase gen und seine verwendung
KR100339316B1 (de)
KR920702417A (ko) Tcf-ii의 아미노산 배열을 코드하는 dna를 함유한 플라스미드, 형질전환세포, 및 이것을 사용하여 생리 활성물질을 생산하는 방법
IE822479L (en) Dna molecules encoding certain mammalian proteins
ES8507473A1 (es) Un procedimiento para preparar un peptido de resina
EP0037723A3 (de) Expression von genomischen Klonen von Hormonen
EP0349342A3 (de) Polypeptide mit zellenverstreuender Aktivität
ATE107665T1 (de) Proteaseresistenter pdgf und dessen verwendungen.

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees